Cannabis Law Report

NOVEMBER 24, 2019

Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy. NICE has made research recommendations on the use of cannabis-based medicinal products for severe treatment-resistant epilepsy. Rationale and impact.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Project CBD

FEBRUARY 28, 2023

CBD sales declined in 2021 for several possible reasons, including legal confusion, a lack of a clear path for FDA regulation, market saturation, and published reports of inaccurate label claims for some CBD products. FDA Intransigence On a federal level, CBD is not considered a legal dietary supplement ingredient. Epilepsy Behav.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Firstly, we contextualise cannabis in terms of its historical usage, its legal status, and research relating to knowledge, attitudes, and usage. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 30, 2019

Illinois and the US territory of Guam legalized adult-use cannabis and its retail sale, medical cannabis programs were enacted and expanded in several states, and 27 states considered legislation that would have legalized adult-use cannabis, a record-high. Continued Protections for State Legal Medical Programs. Erik Altieri.

Legislation 59

Legislation Patients Access Banking 59